Multiple Myeloma Drugs Guide
The multiple myeloma drugs guide offers comprehensive information on multiple myeloma drug treatments.
Myeloma drug information includes what the drug is, dosage amounts, side effects, and the benefits seen within clinical studies. While the type of treatment that your doctor recommends may depend on your multiple myeloma prognosis, learning about your drug treatment options can help you prepare for discussions with your doctor.
Myeloma drug therapies typically serve one of two functions: to control and destroy myeloma cells or to alleviate multiple symptoms, such as bone disease or kidney failure. With that in mind, the myeloma drugs guide focuses on six of the conventional drug treatment options used for both treating myeloma directly or for supportive therapies.
Darzalex™, also known as daratumumab, is the first monoclonal antibody approved for use in multiple myeloma. Darzalex is made by Janssen Biotech and Genmab.
Doxil is a chemotherapy drug used in myeloma treatment. Doxil is an anthracycline antibiotic that works by intercalating the DNA found in multiple myeloma. The drug has been used in traditional chemotherapy regimens for many years.
Empliciti™, also known as elotuzumab, is a monoclonal antibody approved for use in multiple myeloma. Empliciti is made by Bristol-Myers Squibb and AbbVie.
Farydak® is a histone deacetylase inhibitor that is administered in combination with Velcade® (bortezomib) and dexamethasone. It is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication was approved by the FDA on February 23, 2015 under accelerated approval based on progression free survival.
Kyprolis is a selective proteasome inhibitor that acts as an anti-cancer drug treatment for myeloma patients. The Multiple Myeloma Research Foundation has provided assistance in developing Kyprolis over the last 6 years. The drug has showed promise in the treatment of relapsed or refractory multiple myeloma.
The U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib). Ninlaro is the first oral proteasome inhibitor and is approved in combination with Revlimid (lenalidomide) and dexamethasone.
Pomalyst is an anti-angiogenic drug that acts as an immunomodulatory agent. Pomalyst, or Pomalidomid, is similar to Revlimid and Thalomid, but considered to be much more potent. The drug is administered orally and is reserved for patients who have demonstrated myeloma progression within 60 days of their last therapy completion.
Revlimid is an immunomodulatory drug that has significantly improved survival in myeloma. The drug, also known as Lenalidomide, works by inhibiting tumor angiogenesis through induced aptosis, or cell death.
Thalomid is a myeloma drug treatment that works by affecting the immune system. Thalomid, or Thalidomide, was originally developed to treatment insomnia or morning sickness. However, the immunomodulatory drug has shown to be highly effective against multiple myeloma.
Velcade was the first FDA-approved proteasome inhibitor used in the treatment of relapsed multiple myeloma or mantle cell lymphoma. Velcade has been shown to improve response rates following initial myeloma therapies. The drug was originally synthesized in 1995.
For more information on multiple myeloma drugs, consult with a physician. Patients can also explore experimental multiple myeloma treatment drug treatment options.